Objectives: The primary objective of this study was to compare a traditional green KTP laser to a new investigational yellow laser (PhotoLase) in the treatment of facial telangiectasia in terms of the treatment outcomes. The secondary objective was to assess the functionality and reliability of the PhotoLase system from the perspective of the user.
Introduction: Several lasers are used for vascular indications, but the standard lasers are yellow pulsed dye laser (585- or 595-nm) and green potassium titanyl-phosphate (KTP) laser (532-nm), because their wavelengths are close to the absorption peaks (542 and 577 nm) of oxyhaemoglobin. To address the needs of the dermatologic community a novel laser technology, namely optically pumped semiconductor disk laser (SDL), has emerged to provide a compact and cost-effective alternative for a yellow laser source.
Materials / method: The study was a randomized split-face double-blinded study that compared the treatment efficacy of the 532-nm KTP laser and the investigational 585-nm PhotoLase laser. One or two treatments were given based on the response of the first treatment. The improvement of telangiectasia was graded according to a 7-point Telangiectasia Grading Scale (TGS) by the subjects and blinded physicians. The subjects assessed the amount of pain during the treatments using Visual Analogue Scale (VAS), and evaluated adverse effects 2–3 days after the treatment(s) using a self-assessment form.
Results: At least 50% improvement was seen in 15/18 subjects after the first PhotoLase treatment, and a similar result was observed for KTP. There was no difference in the frequency of erythema, crusting or purpura between the devices, but less edema was seen after PhotoLase treatment (p<0.05). Treatment with PhotoLase was evaluated to be 4.7-fold faster than with KTP and the PhotoLase system was more compact, narrower, lighter, and easier to carry than KTP.
Conclusion: The investigational PhotoLase laser enables significantly faster treatments, providing a similar clinical outcome in the treatment of facial telangiectasia.
Divulgação de informações
Você recebeu algum patrocínio para sua pesquisa neste tema?
Não
Você recebeu algum tipo de honorário, pagamento ou outra forma de compensação por seu trabalho neste estudo?
Não
Você possui relação financeira com alguma entidade que possa competir com os medicamentos, materiais ou instrumentos abordados no seu estudo?
Não
Você detém ou pediu a registro de patente para algum dos instrumentos, medicamentos ou materiais abordados no seu estudo?
Não
Este trabalho não recebeu nenhum patrocínio direto ou indireto. O mesmo está sob a própria responsabilidade do seu autor.
